Dermatitis
Amgen and Kyowa Kirin Provide Top-Line Results From Rocatinlimab Phase 3 IGNITE Study in Atopic Dermatitits
Amgen
PR-03-25-NI-03Mar 10, 2025
Announcement
Amgen Announces $1 Billion Manufacturing Expansion in North Carolina
Amgen
PR-12-24-NI-129Dec 06, 2024
COVID-19
Iceland Provides a Picture of the Early Spread of COVID-19 in a Population with a Cohesive Public Health Response
deCODE
PR-M05-20-NI-004May 01, 2020
Facility
Amgen Selects Location for R&D Facility in ihe South San Francisco Biotechnology Hub
Amgen
PR-M12-19-NI-014Dec 10, 2019
Partner
Revolution Medicines and Amgen Partner on Phase 1b Study to Evaluate Combination of RMC-4630 and AMG 510
REVOLUTION Medicines, Inc.
PR-M11-19-NI-004Nov 05, 2019
Strategic Collaboration
Amgen Enters Into Strategic Collaboration With BeiGene To Expand Oncology Presence In China
Amgen
PR-M10-19-NI-048Nov 01, 2019
Drug Pricing
Amgen To Make Repatha® (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
Amgen
PR-M10-19-NI-037Oct 25, 2019
Positive Results
Amgen Announces Positive Results From Two Phase 3 BLINCYTO® Studies In Pediatric Patients
Amgen
PR-M09-19-NI-056Sep 27, 2019
Investment
Rumors Suggest Amgen is Interested in Alexion
Nice Insight
PAO-M00-19-NI-001Sep 04, 2019
M&A
Amgen to Acquire Otezla® for $13.4 Billion in Cash, or Approximately $11.2 Billion Net of Anticipated Future Cash Tax Benefits
Amgen
PR-M08-19-NI-083Aug 29, 2019
KRAS Inhibitor
Amgen Reports Further Success with New KRAS Inhibitor
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M08-19-NI-025Aug 22, 2019
Collaboration
Amgen And Syapse Enter Precision Medicine Collaboration In Oncology
Amgen
PR-M05-19-NI-014May 06, 2019
Launch
Amgen Foundation Launches Amgen Biotech Experience In Tampa, Florida
Amgen Foundation
PR-M04-19-NI-068Apr 22, 2019
Drug Development
EVENITY™ (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
Amgen
PR-M04-19-NI-054Apr 17, 2019
Legal
Amgen Looking to Exit Migraine Collaboration with Novartis
Nice Insight
PAO-M04-19-NI-015Apr 10, 2019
Collaboration
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
Amgen
PR-M03-19-NI-057Mar 21, 2019
Patent
Regeneron and Sanofi Strongly Disagree with Verdict Upholding Three of Five Amgen U.S. Patent Claims Relating to PCSK9 Antibodies
Sanofi
PR-M02-19-NI-059Feb 26, 2019
Collaboration
Amgen, Cytokinetics and Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
Amgen
PR-M02-19-NI-052Feb 22, 2019
Collaboration
Abilita Bio and Amgen Enter Into a Multi-Target Collaboration
Abilita Bio, Inc.
PR-M02-19-NI-035Feb 15, 2019
Biosimilar
Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab
Amgen
PR-M01-19-NI-079Jan 28, 2019